Birchview Capital
Latest statistics and disclosures from Birchview Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are KLAC, BMY, CORT, PRTA, STOK, and represent 40.60% of Birchview Capital's stock portfolio.
- Added to shares of these 10 stocks: KLAC (+$6.5M), CMPX, FOLD, BCYC, GPCR, CYTK, PRTA, SLDB, PHAT, VYGR.
- Started 8 new stock positions in XLV, VYGR, BCYC, AVTX, CMPX, PHVS, GH, NKTR.
- Reduced shares in these 10 stocks: BDSX (-$41M), TVTX, QURE, HROW, AXGN, XNCR, UTHR, ELUT, MLTX, ACAD.
- Sold out of its positions in Accelr8 Technology, Aptevo Therapeutics, BCRX, BPMC, COGT, MLTX, NPCE, TXG, XNCR, WVE.
- Birchview Capital was a net seller of stock by $-28M.
- Birchview Capital has $132M in assets under management (AUM), dropping by 31.53%.
- Central Index Key (CIK): 0001618205
Tip: Access up to 7 years of quarterly data
Positions held by Birchview Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Birchview Capital
Birchview Capital holds 69 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Kla Corporation Com New (KLAC) | 17.8 | $24M | +38% | 22k | 1078.60 |
|
| Bristol Myers Squibb (BMY) | 10.8 | $14M | -2% | 317k | 45.10 |
|
| Corcept Therapeutics Incorporated (CORT) | 4.2 | $5.6M | 67k | 83.11 |
|
|
| Prothena Corp SHS (PRTA) | 4.0 | $5.4M | +21% | 549k | 9.76 |
|
| Stoke Therapeutics (STOK) | 3.7 | $4.9M | 210k | 23.50 |
|
|
| Uniqure Nv SHS (QURE) | 3.5 | $4.6M | -20% | 79k | 58.37 |
|
| Encana Corporation (OVV) | 3.3 | $4.3M | 108k | 40.38 |
|
|
| Neurocrine Biosciences (NBIX) | 3.0 | $4.0M | -7% | 29k | 140.38 |
|
| ACADIA Pharmaceuticals (ACAD) | 2.8 | $3.6M | -8% | 171k | 21.34 |
|
| Protagonist Therapeutics (PTGX) | 2.4 | $3.2M | 48k | 66.43 |
|
|
| Compass Therapeutics (CMPX) | 2.3 | $3.1M | NEW | 873k | 3.50 |
|
| Phreesia (PHR) | 2.0 | $2.7M | 115k | 23.52 |
|
|
| Castle Biosciences (CSTL) | 1.9 | $2.5M | 111k | 22.77 |
|
|
| Structure Therapeutics Spons Adr (GPCR) | 1.6 | $2.2M | +116% | 78k | 28.00 |
|
| Biodesix (BDSX) | 1.6 | $2.2M | -95% | 287k | 7.55 |
|
| Quidel Corporation | 1.6 | $2.1M | 73k | 29.45 |
|
|
| Axogen (AXGN) | 1.6 | $2.1M | -26% | 119k | 17.84 |
|
| Amicus Therapeutics (FOLD) | 1.5 | $2.0M | +803% | 253k | 7.88 |
|
| Harrow Health (HROW) | 1.5 | $1.9M | -33% | 40k | 48.18 |
|
| EQT Corporation (EQT) | 1.4 | $1.9M | 35k | 54.43 |
|
|
| Solid Biosciences Com New (SLDB) | 1.4 | $1.8M | +66% | 297k | 6.17 |
|
| Olema Pharmaceuticals (OLMA) | 1.3 | $1.7M | +29% | 174k | 9.79 |
|
| Cytokinetics (CYTK) | 1.2 | $1.6M | +200% | 30k | 54.96 |
|
| Alkermes SHS (ALKS) | 1.1 | $1.5M | 50k | 30.00 |
|
|
| Foghorn Therapeutics (FHTX) | 1.0 | $1.4M | -9% | 282k | 4.89 |
|
| Novocure Ord Shs (NVCR) | 1.0 | $1.3M | 102k | 12.92 |
|
|
| United Therapeutics Corporation (UTHR) | 0.9 | $1.3M | -29% | 3.0k | 419.21 |
|
| Immunome (IMNM) | 0.9 | $1.2M | +75% | 105k | 11.71 |
|
| Masimo Corporation (MASI) | 0.9 | $1.2M | 8.3k | 147.55 |
|
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.9 | $1.2M | NEW | 154k | 7.74 |
|
| Treace Med Concepts (TMCI) | 0.9 | $1.2M | 177k | 6.71 |
|
|
| Kiniksa Pharmaceuticals | 0.9 | $1.2M | 30k | 38.83 |
|
|
| Outset Med | 0.8 | $1.1M | +127% | 79k | 14.12 |
|
| Inhibrx Biosciences (INBX) | 0.8 | $1.1M | 32k | 33.68 |
|
|
| Docgo (DCGO) | 0.8 | $1.0M | 764k | 1.36 |
|
|
| Intellia Therapeutics (NTLA) | 0.8 | $1.0M | 60k | 17.27 |
|
|
| Travere Therapeutics (TVTX) | 0.8 | $1.0M | -58% | 43k | 23.90 |
|
| Phathom Pharmaceuticals (PHAT) | 0.8 | $1.0M | +240% | 85k | 11.77 |
|
| Scholar Rock Hldg Corp (SRRK) | 0.7 | $968k | +62% | 26k | 37.24 |
|
| Xenon Pharmaceuticals (XENE) | 0.6 | $843k | 21k | 40.15 |
|
|
| Kalvista Pharmaceuticals (KALV) | 0.6 | $816k | 67k | 12.18 |
|
|
| Halozyme Therapeutics (HALO) | 0.6 | $741k | 10k | 73.34 |
|
|
| Axsome Therapeutics (AXSM) | 0.6 | $729k | 6.0k | 121.45 |
|
|
| Freeport-mcmoran Cl-b CL-B (FCX) | 0.5 | $708k | 18k | 39.22 |
|
|
| Ultragenyx Pharmaceutical (RARE) | 0.5 | $662k | +22% | 22k | 30.08 |
|
| Pacific Biosciences of California (PACB) | 0.5 | $640k | +25% | 500k | 1.28 |
|
| Apogee Therapeutics (APGE) | 0.5 | $636k | 16k | 39.73 |
|
|
| Aziyo Biologics (ELUT) | 0.5 | $633k | -38% | 711k | 0.89 |
|
| Voyager Therapeutics (VYGR) | 0.5 | $630k | NEW | 135k | 4.67 |
|
| Alphatec Holdings (ATEC) | 0.4 | $480k | 33k | 14.54 |
|
|
| Bridgebio Pharma (BBIO) | 0.3 | $451k | +73% | 8.7k | 51.94 |
|
| Avalo Therapeutics Com New (AVTX) | 0.3 | $394k | NEW | 31k | 12.71 |
|
| Guardant Health (GH) | 0.3 | $375k | NEW | 6.0k | 62.48 |
|
| Pharvaris N V (PHVS) | 0.3 | $370k | NEW | 15k | 24.95 |
|
| Zenas Biopharma (ZBIO) | 0.3 | $366k | 17k | 22.20 |
|
|
| Gossamer Bio (GOSS) | 0.3 | $363k | 138k | 2.63 |
|
|
| Apellis Pharmaceuticals (APLS) | 0.2 | $317k | 14k | 22.63 |
|
|
| Ventyx Biosciences (VTYX) | 0.2 | $307k | +243% | 99k | 3.11 |
|
| Candel Therapeutics (CADL) | 0.2 | $306k | 60k | 5.10 |
|
|
| Orthopediatrics Corp. (KIDS) | 0.2 | $297k | -38% | 16k | 18.53 |
|
| Tela Bio (TELA) | 0.2 | $231k | 155k | 1.49 |
|
|
| Nektar Therapeutics (NKTR) | 0.2 | $229k | NEW | 4.0k | 56.90 |
|
| Healthcare Select Sector Spdr Fund Sbi Healthcare (XLV) | 0.2 | $209k | NEW | 1.5k | 139.17 |
|
| Karyopharm Therapeutics | 0.1 | $183k | 28k | 6.54 |
|
|
| Applied Therapeutics (APLT) | 0.1 | $136k | -19% | 225k | 0.60 |
|
| Cullinan Oncology (CGEM) | 0.1 | $119k | 20k | 5.93 |
|
|
| Inflarx Nv (IFRX) | 0.1 | $67k | 50k | 1.34 |
|
|
| Alumis (ALMS) | 0.0 | $40k | 10k | 3.99 |
|
|
| Zentalis Pharmaceuticals (ZNTL) | 0.0 | $26k | 17k | 1.51 |
|
Past Filings by Birchview Capital
SEC 13F filings are viewable for Birchview Capital going back to 2014
- Birchview Capital 2025 Q3 filed Nov. 13, 2025
- Birchview Capital 2025 Q2 filed Aug. 14, 2025
- Birchview Capital 2023 Q3 amended filed June 30, 2025
- Birchview Capital 2023 Q4 amended filed June 30, 2025
- Birchview Capital 2024 Q1 amended filed June 30, 2025
- Birchview Capital 2024 Q2 amended filed June 30, 2025
- Birchview Capital 2024 Q3 amended filed June 30, 2025
- Birchview Capital 2024 Q4 amended filed June 30, 2025
- Birchview Capital 2025 Q1 filed May 15, 2025
- Birchview Capital 2024 Q4 filed Feb. 14, 2025
- Birchview Capital 2024 Q3 filed Nov. 14, 2024
- Birchview Capital 2024 Q2 filed Aug. 13, 2024
- Birchview Capital 2024 Q1 filed May 14, 2024
- Birchview Capital 2023 Q4 filed Feb. 14, 2024
- Birchview Capital 2023 Q3 filed Nov. 14, 2023
- Birchview Capital 2023 Q2 filed Aug. 8, 2023